SEC Form 4 · accession 0001179110-15-013306

CymaBay Therapeutics, Inc. · CBAY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Carl Goldfischer

Director

Period of report

Sep 9, 2015

Accepted (ET)

Sep 11, 2015 · 5:28 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001042074

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Sep 9, 2015	S	13	$2.76	D	28	I	By Bay City Capital LLC
Common Stock^F1,F2	Sep 9, 2015	S	13,844	$2.76	D	29,980	I	By The Bay City Capital Fund II, L.P.
Common Stock^F1,F2	Sep 9, 2015	S	905	$2.76	D	1,959	I	By The Bay City Capital Fund II Co-Investment Fund, L.P
Common Stock^F3,F2	Sep 10, 2015	S	15	$2.71	D	13	I	By Bay City Capital LLC
Common Stock^F3,F2	Sep 10, 2015	S	15,474	$2.71	D	14,506	I	By The Bay City Capital Fund II, L.P.
Common Stock^F3,F2	Sep 10, 2015	S	1,011	$2.71	D	948	I	By The Bay City Capital Fund II Co-Investment Fund, L.P.
Common Stock^F4,F2	Sep 11, 2015	S	13	$2.77	D	0	I	By Bay City Capital LLC
Common Stock^F5,F2	Sep 11, 2015	S	14,506	$2.76	D	0	I	By The Bay City Capital Fund II, L.P.
Common Stock^F5,F2	Sep 11, 2015	S	948	$2.76	D	0	I	By The Bay City Capital Fund II Co-Investment Fund, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.70 to $2.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2The Reporting Person is a managing director of Bay City Capital LLC, The Bay City Capital Fund II, L.P. and The Bay City Capital Fund II Co-Investment Fund, L.P (collectively the "Bay City Capital Funds"), and has voting and investment control over the shares owned by the Bay City Capital Funds. The Reporting Person disclaims beneficial ownership of the shares owned by the Bay City Capital Funds except to the extent of his pecuniary interest therein.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.66 to $2.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.69 to $2.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.64 to $2.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.